Weekly Islatravir Lenacapavir HIV Trial Confirms Sustained Suppression

The Weekly islatravir and lenacapavir HIV trial demonstrates that a once-weekly single-tablet combination of islatravir and lenacapavir sustains viral control after a switch from established daily regimens in adults with suppressed HIV-1.

Weekly Suppression Confirmed in Phase 3 Switch Studies

Noninferiority was demonstrated against both bictegravir-based therapy and broader standard-of-care comparators through 48 weeks, with no new safety signals detected. These outcomes position the regimen as a candidate for the initial oral therapy administered on a weekly schedule.

Two parallel multicenter trials assessed the switch strategy under distinct blinding conditions. ISLEND-1 employed a double-blind, active-controlled design that randomized participants to the investigational tablet plus placebo or continued bictegravir-based therapy plus placebo, while ISLEND-2 used an open-label comparison against ongoing daily regimens containing two or three antiretrovirals. Both studies applied the FDA snapshot algorithm to classify the primary endpoint of HIV-1 RNA at or above 50 copies per milliliter at week 48, with secondary virologic, immunologic, and tolerability measures tracked through the same time point.

Low Failure Rates and Improved Satisfaction

Across the two trials, fewer than 1 percent of participants receiving the weekly regimen met the virologic failure threshold at week 48, rates that aligned closely with those observed in the daily-therapy arms. Treatment-emergent adverse events leading to discontinuation remained infrequent, and CD4+ T-cell counts together with lymphocyte counts showed no meaningful decline in either group. Participants who transitioned to the weekly tablet additionally recorded improved satisfaction scores and reduced perceived treatment burden relative to continued daily dosing.

Evidence for Adherence Models and Access Planning

The demonstrated maintenance of suppression with a reduced dosing frequency supplies health-economic models with direct evidence on adherence-related outcomes that may influence long-term persistence estimates. Market-access planning can incorporate the observed patient-reported advantages when constructing value dossiers that compare dosing convenience against existing single-tablet daily options. Reimbursement frameworks evaluating novel antiretroviral combinations will therefore have week-48 data on both efficacy equivalence and tolerability to inform formulary positioning and potential pricing negotiations.